In a landmark move poised to reshape Alzheimer's disease management for millions, China has formally included the innovative treatment Leqembi (lecanemab) in its newly established "Commercial Insurance Innovative Drug List." This strategic decision, announced by BioArctic's partner Eisai,
A Paradigm Shift: Redefining Growth in a Digital-First World The insurance industry is in the midst of a profound transformation, moving away from traditional, slow-growth models toward a dynamic, technology-infused future. A wave of recent announcements from key players reveals a clear and
A Market's Soul on Trial The Lloyd’s of London insurance market, an institution steeped in centuries of tradition and defined by its global influence, is once again facing a profound identity crisis that strikes at the very heart of its corporate character. The decision to reopen an investigation
In an era where digital presence is synonymous with business survival, a deeply concerning paradox has emerged for the United Kingdom's small and medium-sized enterprises, with data revealing that a staggering majority have suffered a cyber incident yet remain critically under-protected. This
The delegated authority broking model that once defined the industry is no longer viable, as the ground has irrevocably shifted beneath it. With delegated business now accounting for approximately 45% of Lloyd's of London's total premium and on a trajectory to become the dominant majority, the
Imagine an industry at a pivotal moment, where nearly every professional agrees that the tools they rely on are holding them back, yet the path forward is fraught with obstacles. This is the reality for the insurance sector today, where a staggering 73% of leaders are gearing up for significant
